"The
Report Global Gastrointestinal Drug Market to 2022 - Pipeline
Characterized by Emerging Biologic Therapies, While TNF Inhibitors
and PPIs Continue to Dominate Therapy Landscape provides information
on pricing, market analysis, shares, forecast, and company profiles
for key industry participants. - MarketResearchReports.biz"
Disease
and disorders involving the gastrointestinal system are among the
most common conditions encountered worldwide, and many of them can
have a significant impact on quality of life. The direct and indirect
socio-economic burden associated with gastrointestinal disorders is
profound. The direct costs of medical consultations and treatments in
the US for gastroesophageal reflux disease alone are estimated to
amount to $9.3 billion, while the indirect costs due to absenteeism
and impairment in work performance total $75 billion (Chait, 2010).
Despite
the significant global socio-economic burden, many gastrointestinal
disorders are still poorly understood, and there is a significant
unmet need for novel, safe and effective therapies, as treatment
options are often lacking, causing many patients to be dissatisfied
with their treatment. The unmet need and demand for better treatments
and the high prevalence of digestive conditions make the
gastrointestinal market an attractive candidate for therapeutic
development.
This
report covers all gastrointestinal disorders, but there is a
particular focus on three key diseases: gastroesophageal reflux
disease, irritable bowel syndrome and inflammatory bowel disease. The
global gastrointestinal market was valued at $35.7 billion in 2015
and is projected to grow at a compound annual growth rate (CAGR) of
4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs)
and tumor necrosis factor (TNF)-α inhibitors generate the largest
revenues and continue to retain commercial prominence. Key drivers of
market growth will be the uptake of recently approved premium
products, rising prevalence, and promising late-stage products,
including a number of biologic therapies that are expected to be
highly valuable.
View
Report At :http://www.marketresearchreports.biz/analysis/855887
Scope
The gastrointestinal market
landscape is expected to change substantially with the advent of
promising novel pipeline products.
There are 937
gastrointestinal pipeline products in active development, of which
small molecules and biologics account for 53% and 38%, respectively.
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
Global revenue for the
gastrointestinal market is forecast to grow at a CAGR of 4.45%, from
$35.7 billion in 2015 to $48.4 billion in 2022.
- Which products will be the biggest drivers for market growth?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the gastrointestinal market set to change?
- What CAGR will these companies register in the forecast period?
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/855887
Reasons to buy
This report will allow you
to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
- Visualize the composition of the gastrointestinal market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
- Analyze the gastrointestinal pipeline, stratifying it by stage of development, molecule type and molecular target and providing a granular breakdown across key indications.
- Understand the growth in patient epidemiology and market revenue for the gastrointestinal market globally and across the key players and product types.
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various gastrointestinal conditions.
- Identify commercial opportunities in the gastrointestinal deals landscape by analyzing trends in licensing and co-development deals.
Table
of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.2 Symptoms 10
2.2.1 Gastroesophageal Reflux
Disease 10
2.2.2 Irritable Bowel Syndrome
10
2.2.3 Inflammatory Bowel
Disease 10
2.3 Etiology and
Pathophysiology 11
2.3.1 Gastroesophageal Reflux
Disease 11
2.3.2 Irritable Bowel Syndrome
12
2.3.3 Inflammatory Bowel
Disease 14
2.4 Co-morbidities and
Complications 15
2.5 Epidemiology Patterns and
Forecasts - Prevalence and Patient Segmentation 16
2.5.1 Gastroesophageal Reflux
Disease 17
2.5.2 Irritable Bowel Syndrome
17
2.5.3 Inflammatory Bowel
Disease 18
2.6 Treatment 19
2.6.1 Acid-Controlling Agents
19
2.6.2
Anticholinergics/Antispasmodics 20
2.6.3 Gastric Stimulants,
Laxatives and Antidiarrheals 20
2.6.4 Anti-inflammatory and
Systemic Immunosuppressive Agents 21
2.6.5 Biologics 22
3 Key Marketed Products 23
3.1 Overview 23
3.2 Humira (adalimumab) 24
3.3 Remicade (infliximab) 26
3.4 Soliris (eculizumab) 28
3.5 Tysabri (natalizumab) 29
3.6 Nexium (esomeprazole
magnesium) 31
3.7 Entyvio (vedolizumab) 33
3.8 Protonix (pantoprazole) 35
3.9 Ocaliva (obeticholic acid)
37
3.10 Dexilant (dexlansoprazole)
38
3.11 Amitiza (lubiprostone) 40
3.12 Takecab (vonoprazan) 41
3.13 Linzess (linaclotide) 43
4 Pipeline Landscape Assessment
45
4.1 Overview 45
4.2 Molecule Types in the
Pipeline 47
4.3 Molecular Targets in the
Pipeline 48
4.4 Clinical Trials Landscape
50
4.4.1 Clinical Trial Failure
Rates 51
4.4.2 Clinical Trial Duration
54
4.4.3 Clinical Trial Size 58
4.4.4 Cumulative Clinical Trial
Size 61
4.5 Late-Stage Drugs of the
Developmental Pipeline 64
4.5.1 RPC1063 (ozanimod) -
Celgene 64
4.5.2 GED-0301 (mongersen) -
Celgene 65
4.5.3 Stelara (ustekinumab) -
Johnson & Johnson 66
4.5.4 Victoza (liraglutide) -
Novo Nordisk 68
4.5.5 Plecanatide - Synergy
Pharmaceuticals 69
4.6 Conclusion 70
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment